You are here: Industry Insights > Lilly

News List

CHMP issues positive opinion for Lilly’s COVID-19 antibodies pharmatimes
March 08, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Eli Lilly’s COVID-19 antibodies bamlanivimab and etesevimab.
Lilly’s tirzepatide claims head-to-head trial win against injectable semaglutide pharmatimes
March 05, 2021
Eli Lilly’s investigational treatment tirzepatide has demonstrated superior A1C and body weight reduction compared to injectable semaglutide in adults with type 2 diabetes.
U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail contractpharma
March 02, 2021
The U.S. government will purchase a minimum of 100,000 doses of Lilly’s bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together.
Eli Lilly enters into $960 million deal with Rigel Pharma to develop autoimmune therapy expresspharma
February 20, 2021
Under the deal, Lilly will foot the costs of global commercialisation for the therapy, R552, and Rigel will have the right to co-sell the treatment in the US.
Regor Therapeutics Announces Completion of $90 Million Series B Financing prnasia
February 19, 2021
Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing.
NICE rejects Lilly’s Verzenios for advanced breast cancer pharmatimes
February 19, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.
Lilly Apoints SVP, CFO contractpharma
February 10, 2021
Anat Ashkenazi replaces Josh Smiley, who has resigned and will be leaving the company.
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19 expresspharma
February 10, 2021
Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a million doses by mid-2021.
Financial Report. Lilly contractpharma
February 07, 2021
Recognizes worldwide revenue of $871.2 million in the quarter for bamlanivimab COVID-19 treatment.
Lilly to provide antibody therapies at Indiana hospitals for treating COVID-19 pharmaceutical-business-review
February 05, 2021
Eli Lilly and Company (Lilly) has joined hands with local health systems in the US state of Indiana to provide antibody therapies through dedicated infusion centre locations that will offer treatments for patients with COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page